CoChat
Sign Up
Cited by 143Wnt/β-catenin signaling in development and cancerHepatocellular Carcinoma Treatment and PrognosisLiver physiology and pathology

Wnt/β-Catenin Signaling in Liver Cancers

Open access
Wang, Wenhui, Smits, Ron, Hao, Haiping, He, Chaoyong·2019·Cancers
DOI 10.3390/cancers11070926PMC PMC6679127
Open this paper in CoChat — free accountOpen PDF

Abstract

Liver cancer is among the leading global healthcare issues associated with high morbidity and mortality. Liver cancer consists of hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), hepatoblastoma (HB), and several other rare tumors. Progression has been witnessed in understanding the interactions between etiological as well as environmental factors and the host in the development of liver cancers. However, the pathogenesis remains poorly understood, hampering the design of rational strategies aiding in preventing liver cancers. Accumulating evidence demonstrates that aberrant activation of the Wnt/β-catenin signaling pathway plays an important role in the initiation and progression of HCC, CCA, and HB. Targeting Wnt/β-catenin signaling potentiates a novel avenue for liver cancer treatment, which may benefit from the development of numerous small-molecule inhibitors and biologic agents in this field. In this review, we discuss the interaction between various etiological factors and components of Wnt/β-catenin signaling early in the precancerous lesion and the acquired mechanisms to further enhance Wnt/β-catenin signaling to promote robust cancer formation at later stages. Additionally, we shed light on current relevant inhibitors tested in liver cancers and provide future perspectives for preclinical and clinical liver cancer studies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers11070926

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Activating mutations in Wnt signaling components are common in liver cancer.

    “activating mutations in Wnt signaling components are common in liver cancer (41, 42)”

    From Wnt signaling regulates hepatocyte cell division by a transcriptional repressor cascade (2022) · cites this paper as [42]

    Section 4.3 reports activating CTNNB1 mutations in 60–80% of hepatoblastomas, and section 4.1 reports them in 15–25% of hepatocellular carcinomas. But section 4.2 says mutations in related genes are less frequent in cholangiocarcinoma, so the unqualified claim across liver cancers overstates the evidence. Page numbers are unavailable in our copy. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

  • Activating mutations in Wnt signaling components are common in liver cancer.

    “Interestingly, activating mutations in Wnt signaling components are common in liver cancer (Nusse and Clevers 2017;Wang et al. 2019)”

    From Hepatocyte Cell Cycle Progression Depends on a Transcriptional Repressor Cascade Downstream of Wnt Signaling (2021) · cites this paper as Wang et al. 2019

    Section 4.1 reports activating CTNNB1 mutations in 15–25% of hepatocellular carcinomas, and Section 4.3 reports them in 60–80% of hepatoblastomas. The unqualified claim is broader than those findings: Section 4.2 says mutations in related genes are less frequent in cholangiocarcinoma. Page numbers were not provided in our copy. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

No citation lists for this paper

No citation lists for this paper yet — checked again daily.

References 130 · Cited by 143

Research works printed but not linked: 126

  1. [1]Farazi P.A. DePinho R.A. Hepatocellular carcinoma pathogenesis: From genes to environment Nat. Rev. Cancer 2006 6 674 687 10.1038/nrc1934 16929323 · DOI
  2. [2]Razumilava N. Gores G.J. Cholangiocarcinoma Lancet 2014 383 2168 2179 10.1016/S0140-6736(13)61903-0 24581682 PMC4069226 · DOI
  3. [3]Darbari A. Sabin K.M. Shapiro C.N. Schwarz K.B. Epidemiology of primary hepatic malignancies in U.S. children Hepatology 2003 38 560 566 10.1053/jhep.2003.50375 12939582 · DOI
  4. [4]Aretz S. Koch A. Uhlhaas S. Friedl W. Propping P. von Schweinitz D. Pietsch T. Should children at risk for familial adenomatous polyposis be screened for hepatoblastoma and children with apparently sporadic hepatoblastoma be screened for APC germline mutations? Pediatr. Blood Cancer 2006 47 811 818 10.1002/pbc.20698 16317745 · DOI
  5. [5]Qu B. Liu B.R. Du Y.J. Chen J. Cheng Y.Q. Xu W. Wang X.H. Wnt/β-catenin signaling pathway may regulate the expression of angiogenic growth factors in hepatocellular carcinoma Oncol. Lett. 2014 7 1175 1178 10.3892/ol.2014.1828 24944688 PMC3961220 · DOI
  6. [6]Anastas J.N. Moon R.T. WNT signalling pathways as therapeutic targets in cancer Nat. Rev. Cancer 2012 13 11 26 10.1038/nrc3419 23258168 · DOI
  7. [7]Klaus A. Birchmeier W. Wnt signalling and its impact on development and cancer Nat. Rev. Cancer 2008 8 387 398 10.1038/nrc2389 18432252 · DOI · Paper page
  8. [8]Wang W. Pan Q. Fuhler G.M. Smits R. Peppelenbosch M.P. Action and function of Wnt/beta-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma J. Gastroenterol. 2017 52 419 431 10.1007/s00535-016-1299-5 28035485 PMC5357489 · DOI
  9. [9]Peifer M. Polakis P. Wnt signaling in oncogenesis and embryogenesis—A look outside the nucleus Science 2000 287 1606 1609 10.1126/science.287.5458.1606 10733430 · DOI · Paper page
  10. [10]Dahmani R. Just P.A. Perret C. The Wnt/beta-catenin pathway as a therapeutic target in human hepatocellular carcinoma Clin. Res. Hepatol. Gastroenterol. 2011 35 709 713 10.1016/j.clinre.2011.05.010 21778132 · DOI
  11. [11]Liu X. Zhang B. McBride J.D. Zhou K. Lee K. Zhou Y. Liu Z. Ma J.X. Antiangiogenic and antineuroinflammatory effects of kallistatin through interactions with the canonical Wnt pathway Diabetes 2013 62 4228 4238 10.2337/db12-1710 23884893 PMC3837048 · DOI
  12. [12]Hart M. Concordet J.P. Lassot I. Albert I. del los Santos R. Durand H. Perret C. Rubinfeld B. Margottin F. Benarous R. The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell Curr. Biol. 1999 9 207 210 10.1016/S0960-9822(99)80091-8 10074433 · DOI
  13. [13]Zhong Y. Katavolos P. Nguyen T. Lau T. Boggs J. Sambrone A. Kan D. Merchant M. Harstad E. Diaz D. Tankyrase Inhibition Causes Reversible Intestinal Toxicity in Mice with a Therapeutic Index <1 Toxicol. Pathol. 2016 44 267 278 10.1177/0192623315621192 26692561 · DOI
  14. [15]Tian Y. Mok M.T. Yang P. Cheng A.S. Epigenetic Activation of Wnt/beta-Catenin Signaling in NAFLD-Associated Hepatocarcinogenesis Cancers (Basel) 2016 8 76 10.3390/cancers8080076 27556491 PMC4999785 · DOI
  15. [16]Sharma M. Jamieson C. Johnson M. Molloy M.P. Henderson B.R. Specific armadillo repeat sequences facilitate beta-catenin nuclear transport in live cells via direct binding to nucleoporins Nup62, Nup153, and RanBP2/Nup358 J. Biol. Chem. 2012 287 819 831 10.1074/jbc.M111.299099 22110128 PMC3256910 · DOI
  16. [17]Ma L. Wei W. Chua M.-S. So S. WNT/β-catenin pathway activation in hepatocellular carcinoma: A clinical perspective Gastrointest. Cancer Targets Ther. 2014 4 49 63 10.2147/GICTT.S44256 · DOI · Paper page
  17. [18]Lau C.C. Sun T. Ching A.K. He M. Li J.W. Wong A.M. Co N.N. Chan A.W. Li P.S. Lung R.W. Viral-human chimeric transcript predisposes risk to liver cancer development and progression Cancer Cell 2014 25 335 349 10.1016/j.ccr.2014.01.030 24582836 · DOI
  18. [19]Tiollais P. Pourcel C. Dejean A. The hepatitis B virus Nature 1985 317 489 495 10.1038/317489a0 2995835 · DOI
  19. [20]Xie Q. Chen L. Shan X. Shan X. Tang J. Zhou F. Chen Q. Quan H. Nie D. Zhang W. Epigenetic silencing of SFRP1 and SFRP5 by hepatitis B virus X protein enhances hepatoma cell tumorigenicity through Wnt signaling pathway Int. J. Cancer 2014 135 635 646 10.1002/ijc.28697 24374650 · DOI
  20. [21]Hsieh A. Kim H.S. Lim S.O. Yu D.Y. Jung G. Hepatitis B viral X protein interacts with tumor suppressor adenomatous polyposis coli to activate Wnt/beta-catenin signaling Cancer Lett. 2011 300 162 172 10.1016/j.canlet.2010.09.018 20971552 · DOI
  21. [22]Cha M.Y. Kim C.M. Park Y.M. Ryu W.S. Hepatitis B virus X protein is essential for the activation of Wnt/beta-catenin signaling in hepatoma cells Hepatology 2004 39 1683 1693 10.1002/hep.20245 15185310 · DOI
  22. [23]Yu Z. Gao Y.Q. Feng H. Lee Y.Y. Li M.S. Tian Y. Go M.Y. Yu D.Y. Cheung Y.S. Lai P.B. Cell cycle-related kinase mediates viral-host signalling to promote hepatitis B virus-associated hepatocarcinogenesis Gut 2014 63 1793 1804 10.1136/gutjnl-2013-305584 24440987 · DOI
  23. [24]Daud M. Rana M.A. Husnain T. Ijaz B. Modulation of Wnt signaling pathway by hepatitis B virus Arch. Virol. 2017 162 2937 2947 10.1007/s00705-017-3462-6 28685286 · DOI
  24. [25]Tian X. Zhao C. Ren J. Ma Z.M. Xie Y.H. Wen Y.M. Gene-expression profiles of a hepatitis B small surface antigen-secreting cell line reveal upregulation of lymphoid enhancer-binding factor 1 J. Gen. Virol. 2007 88 2966 2976 10.1099/vir.0.83108-0 17947518 · DOI
  25. [26]Tian X. Li J. Ma Z.M. Zhao C. Wan D.F. Wen Y.M. Role of hepatitis B surface antigen in the development of hepatocellular carcinoma: Regulation of lymphoid enhancer-binding factor 1 J. Exp. Clin. Cancer Res. 2009 28 58 10.1186/1756-9966-28-58 19402906 PMC2678988 · DOI
  26. [27]Niknafs Y.S. Chinnaiyan A.M. RNA identity crisis: Hepatitis B walks the LINE Cancer Cell 2014 25 259 260 10.1016/j.ccr.2014.02.011 24651004 · DOI
  27. [28]Budzinska M.A. Shackel N.A. Urban S. Tu T. Cellular Genomic Sites of Hepatitis B Virus DNA Integration Genes (Basel) 2018 9 365 10.3390/genes9070365 PMC6071206 30037029 · DOI
  28. [29]Cao Q. Imbeaud S. Datta S. Zucman-Rossi J. Authors’ response: Virus-host interactions in HBV-related hepatocellular carcinoma: More to be revealed? Gut 2015 64 853 854 10.1136/gutjnl-2014-308482 25331453 · DOI
  29. [30]Lin M.V. King L.Y. Chung R.T. Hepatitis C virus-associated cancer Annu. Rev. Pathol. 2015 10 345 370 10.1146/annurev-pathol-012414-040323 25387053 · DOI
  30. [31]McLauchlan J. Properties of the hepatitis C virus core protein: A structural protein that modulates cellular processes J. Viral. Hepat. 2000 7 2 14 10.1046/j.1365-2893.2000.00201.x 10718937 · DOI
  31. [32]Ray R.B. Ray R. Hepatitis C virus core protein: Intriguing properties and functional relevance FEMS Microbiol. Lett. 2001 202 149 156 10.1111/j.1574-6968.2001.tb10796.x 11520607 · DOI
  32. [33]Fukutomi T. Zhou Y. Kawai S. Eguchi H. Wands J.R. Li J. Hepatitis C virus core protein stimulates hepatocyte growth: Correlation with upregulation of wnt-1 expression Hepatology 2005 41 1096 1105 10.1002/hep.20668 15841445 · DOI
  33. [34]Liu J. Ding X. Tang J. Cao Y. Hu P. Zhou F. Shan X. Cai X. Chen Q. Ling N. Enhancement of canonical Wnt/β-catenin signaling activity by HCV core protein promotes cell growth of hepatocellular carcinoma cells PLoS ONE 2011 6 e27496 10.1371/journal.pone.0027496 22110662 PMC3216985 · DOI
  34. [35]Umer M. Qureshi S.A. Hashmi Z.Y. Raza A. Ahmad J. Rahman M. Iqbal M. Promoter hypermethylation of Wnt pathway inhibitors in hepatitis C virus-induced multistep hepatocarcinogenesis Virol. J. 2014 11 117 10.1186/1743-422X-11-117 24947038 PMC4076499 · DOI
  35. [36]Quan H. Zhou F. Nie D. Chen Q. Cai X. Shan X. Zhou Z. Chen K. Huang A. Li S. Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial—mesenchymal transition Oncogene 2014 33 2826 2835 10.1038/onc.2013.225 23770846 · DOI
  36. [37]Ripoli M. Barbano R. Balsamo T. Piccoli C. Brunetti V. Coco M. Mazzoccoli G. Vinciguerra M. Pazienza V. Hypermethylated levels of E-cadherin promoter in Huh-7 cells expressing the HCV core protein Virus Res. 2011 160 74 81 10.1016/j.virusres.2011.05.014 21640770 · DOI
  37. [38]Sawey E.T. Chanrion M. Cai C. Wu G. Zhang J. Zender L. Zhao A. Busuttil R.W. Yee H. Stein L. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening Cancer Cell 2011 19 347 358 10.1016/j.ccr.2011.01.040 21397858 PMC3061399 · DOI
  38. [39]Park C.Y. Choi S.H. Kang S.M. Kang J.I. Ahn B.Y. Kim H. Jung G. Choi K.Y. Hwang S.B. Nonstructural 5A protein activates beta-catenin signaling cascades: Implication of hepatitis C virus-induced liver pathogenesis J. Hepatol. 2009 51 853 864 10.1016/j.jhep.2009.06.026 19726098 · DOI
  39. [40]Street A. Macdonald A. Crowder K. Harris M. The Hepatitis C virus NS5A protein activates a phosphoinositide 3-kinase-dependent survival signaling cascade J. Biol. Chem. 2004 279 12232 12241 10.1074/jbc.M312245200 14709551 · DOI
  40. [41]Macdonald A. Harris M. Hepatitis C virus NS5A: Tales of a promiscuous protein J. Gen. Virol. 2004 85 2485 2502 10.1099/vir.0.80204-0 15302943 · DOI
  41. [42]Street A. Macdonald A. McCormick C. Harris M. Hepatitis C virus NS5A-mediated activation of phosphoinositide 3-kinase results in stabilization of cellular β-catenin and stimulation of β-catenin-responsive transcription J. Virol. 2005 79 5006 5016 10.1128/JVI.79.8.5006-5016.2005 15795286 PMC1069556 · DOI
  42. [43]Balasubramanian A. Ganju R.K. Groopman J.E. Hepatitis C virus and HIV envelope proteins collaboratively mediate interleukin-8 secretion through activation of p38 MAP kinase and SHP2 in hepatocytes J. Biol. Chem. 2003 278 35755 35766 10.1074/jbc.M302889200 12824191 · DOI
  43. [44]Takahashi A. Tsutsumi R. Kikuchi I. Obuse C. Saito Y. Seidi A. Karisch R. Fernandez M. Cho T. Ohnishi N. SHP2 tyrosine phosphatase converts parafibromin/Cdc73 from a tumor suppressor to an oncogenic driver Mol. Cell 2011 43 45 56 10.1016/j.molcel.2011.05.014 21726809 PMC5101830 · DOI
  44. [45]Zhang Y. Wei W. Cheng N. Wang K. Li B. Jiang X. Sun S. Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling Hepatology 2012 56 1631 1640 10.1002/hep.25849 22610915 · DOI
  45. [46]Israsena N. Hu M. Fu W. Kan L. Kessler J.A. The presence of FGF2 signaling determines whether β-catenin exerts effects on proliferation or neuronal differentiation of neural stem cells Dev. Biol. 2004 268 220 231 10.1016/j.ydbio.2003.12.024 15031118 · DOI
  46. [47]Igloi Z. Kazlauskas A. Saksela K. Macdonald A. Mankouri J. Harris M. The hepatitis C virus NS5A protein blocks EGFR degradation via a proline motif dependent interaction J. Gen. Virol. 2015 96 2133 2144 10.1099/vir.0.000145 25872741 PMC4681064 · DOI
  47. [48]Civenni G. Holbro T. Hynes N.E. Wnt1 and Wnt5a induce cyclin D1 expression through ErbB1 transactivation in HC11 mammary epithelial cells EMBO Rep. 2003 4 166 171 10.1038/sj.embor.embor735 12612606 PMC1315833 · DOI
  48. [49]Meyer K. Kwon Y.-C. Liu S. Hagedorn C.H. Ray R.B. Ray R. Interferon-α inducible protein 6 impairs EGFR activation by CD81 and inhibits hepatitis C virus infection Sci. Rep. 2015 5 9012 10.1038/srep09012 25757571 PMC4355636 · DOI
  49. [50]Diao J. Pantua H. Ngu H. Komuves L. Diehl L. Schaefer G. Kapadia S.B. Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry J. Virol. 2012 86 10935 10949 10.1128/JVI.00750-12 22855500 PMC3457153 · DOI
  50. [51]Katoh M. Katoh M. Review Cross-talk of WNT and FGF Signaling Pathways at GSK3β to Regulate β-Catenin and SNAIL Signaling Cascades Cancer Biol. Ther. 2006 5 1059 1064 10.4161/cbt.5.9.3151 16940750 · DOI · Paper page
  51. [52]Van N.D. Falk C.S. Vondran F.W. Helfritz F. Wedemeyer H. Manns M.P. Ciesek S. von Hahn T. Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators Gut 2015 65 1015 1023 10.1136/gutjnl-2014-308003 25800783 PMC4893125 · DOI
  52. [53]Huang C.K. Yu T. de la Monte S.M. Wands J.R. Derdak Z. Kim M. Restoration of Wnt/beta-catenin signaling attenuates alcoholic liver disease progression in a rat model J. Hepatol. 2015 63 191 198 10.1016/j.jhep.2015.02.030 25724365 PMC4475483 · DOI
  53. [54]Xu C.Q. de la Monte S.M. Tong M. Huang C.K. Kim M. Chronic Ethanol-Induced Impairment of Wnt/beta-Catenin Signaling is Attenuated by PPAR-delta Agonist Alcohol. Clin. Exp. Res. 2015 39 969 979 10.1111/acer.12727 25903395 PMC4452420 · DOI
  54. [55]Behari J. Sylvester K.G. Role of the Wnt/beta-Catenin Pathway in the Pathogenesis of Alcoholic Liver Disease Curr. Mol. Pharm. 2017 10 186 194 10.2174/1874467208666150817111256 26278392 · DOI
  55. [56]Liu S. Yeh T.H. Singh V.P. Shiva S. Krauland L. Li H. Zhang P. Kharbanda K. Ritov V. Monga S.P. Beta-catenin is essential for ethanol metabolism and protection against alcohol-mediated liver steatosis in mice Hepatology 2012 55 931 940 10.1002/hep.24766 22031168 PMC3288318 · DOI · Paper page
  56. [57]Lehwald N. Tao G.Z. Jang K.Y. Papandreou I. Liu B. Liu B. Pysz M.A. Willmann J.K. Knoefel W.T. Denko N.C. Beta-Catenin regulates hepatic mitochondrial function and energy balance in mice Gastroenterology 2012 143 754 764 10.1053/j.gastro.2012.05.048 22684045 PMC12045480 · DOI · Paper page
  57. [58]Mercer K.E. Hennings L. Ronis M.J. Alcohol consumption, Wnt/beta-catenin signaling, and hepatocarcinogenesis Adv. Exp. Med. Biol. 2015 815 185 195 10.1007/978-3-319-09614-8_11 25427908 PMC5600155 · DOI
  58. [60]Bhala N. Angulo P. van der Poorten D. Lee E. Hui J.M. Saracco G. Adams L.A. Charatcharoenwitthaya P. Topping J.H. Bugianesi E. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study Hepatology 2011 54 1208 1216 10.1002/hep.24491 21688282 PMC3238674 · DOI
  59. [61]Takada I. Kouzmenko A.P. Kato S. Wnt and PPARgamma signaling in osteoblastogenesis and adipogenesis Nat. Rev. Rheumatol. 2009 5 442 447 10.1038/nrrheum.2009.137 19581903 · DOI
  60. [62]Ross S.E. Hemati N. Longo K.A. Bennett C.N. Lucas P.C. Erickson R.L. MacDougald O.A. Inhibition of adipogenesis by Wnt signaling Science 2000 289 950 953 10.1126/science.289.5481.950 10937998 · DOI
  61. [63]Go G.W. Srivastava R. Hernandez-Ono A. Gang G. Smith S.B. Booth C.J. Ginsberg H.N. Mani A. The combined hyperlipidemia caused by impaired Wnt-LRP6 signaling is reversed by Wnt3a rescue Cell Metab. 2014 19 209 220 10.1016/j.cmet.2013.11.023 24506864 PMC3920193 · DOI
  62. [64]Go G.W. Low-Density Lipoprotein Receptor-Related Protein 6 (LRP6) Is a Novel Nutritional Therapeutic Target for Hyperlipidemia, Non-Alcoholic Fatty Liver Disease, and Atherosclerosis Nutrients 2015 7 4453 4464 10.3390/nu7064453 26046396 PMC4488795 · DOI
  63. [65]Wang S. Song K. Srivastava R. Dong C. Go G.W. Li N. Iwakiri Y. Mani A. Nonalcoholic fatty liver disease induced by noncanonical Wnt and its rescue by Wnt3a FASEB J. 2015 29 3436 3445 10.1096/fj.15-271171 25917329 PMC4511193 · DOI
  64. [66]Teratani T. Tomita K. Suzuki T. Furuhashi H. Irie R. Nishikawa M. Yamamoto J. Hibi T. Miura S. Minamino T. Aortic carboxypeptidase-like protein, a WNT ligand, exacerbates nonalcoholic steatohepatitis J. Clin. Invest. 2018 128 1581 1596 10.1172/JCI92863 29553485 PMC5873845 · DOI
  65. [67]Debebe A. Medina V. Chen C.Y. Mahajan I.M. Jia C. Fu D. He L. Zeng N. Stiles B.W. Chen C.L. Wnt/beta-catenin activation and macrophage induction during liver cancer development following steatosis Oncogene 2017 36 6020 6029 10.1038/onc.2017.207 28671671 PMC5666317 · DOI
  66. [68]Tian Y. Wong V.W. Wong G.L. Yang W. Sun H. Shen J. Tong J.H. Go M.Y. Cheung Y.S. Lai P.B. Histone Deacetylase HDAC8 Promotes Insulin Resistance and beta-Catenin Activation in NAFLD-Associated Hepatocellular Carcinoma Cancer Res. 2015 75 4803 4816 10.1158/0008-5472.CAN-14-3786 26383163 · DOI
  67. [69]Rushing B.R. Selim M.I. Aflatoxin B1: A review on metabolism, toxicity, occurrence in food, occupational exposure, and detoxification methods Food Chem. Toxicol. 2019 124 81 100 10.1016/j.fct.2018.11.047 30468841 · DOI · Paper page
  68. [70]Hussain S.P. Schwank J. Staib F. Wang X.W. Harris C.C. TP53 mutations and hepatocellular carcinoma: Insights into the etiology and pathogenesis of liver cancer Oncogene 2007 26 2166 2176 10.1038/sj.onc.1210279 17401425 · DOI
  69. [71]Fang Y. Feng Y. Wu T. Srinivas S. Yang W. Fan J. Yang C. Wang S. Aflatoxin B1 negatively regulates Wnt/beta-catenin signaling pathway through activating miR-33a PLoS ONE 2013 8 e73004 10.1371/journal.pone.0073004 24015284 PMC3754916 · DOI
  70. [72]Zhu L. Gao J. Huang K. Luo Y. Zhang B. Xu W. miR-34a screened by miRNA profiling negatively regulates Wnt/beta-catenin signaling pathway in Aflatoxin B1 induced hepatotoxicity Sci. Rep. 2015 5 16732 10.1038/srep16732 26567713 PMC4645126 · DOI
  71. [73]Devereux T.R. Stern M.C. Flake G.P. Yu M.C. Zhang Z.Q. London S.J. Taylor J.A. CTNNB1 mutations and beta-catenin protein accumulation in human hepatocellular carcinomas associated with high exposure to aflatoxin B1 Mol. Carcinog. 2001 31 68 73 10.1002/mc.1041 11429783 · DOI
  72. [74]Nhieu J.T. Renard C.A. Wei Y. Cherqui D. Zafrani E.S. Buendia M.A. Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation Am. J. Pathol. 1999 155 703 710 10.1016/S0002-9440(10)65168-1 10487827 PMC1866892 · DOI
  73. [76]Wong C.M. Fan S.T. Ng I.O. beta-Catenin mutation and overexpression in hepatocellular carcinoma: Clinicopathologic and prognostic significance Cancer 2001 92 136 145 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R 11443619 · DOI
  74. [77]Lin Y.T. Chao C.C. Identification of the beta-catenin/JNK/prothymosin-alpha axis as a novel target of sorafenib in hepatocellular carcinoma cells Oncotarget 2015 6 38999 39017 10.18632/oncotarget.5738 26517516 PMC4770752 · DOI
  75. [78]Laurent-Puig P. Zucman-Rossi J. Genetics of hepatocellular tumors Oncogene 2006 25 3778 3786 10.1038/sj.onc.1209547 16799619 · DOI
  76. [79]Fujimoto A. Totoki Y. Abe T. Boroevich K.A. Hosoda F. Nguyen H.H. Aoki M. Hosono N. Kubo M. Miya F. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators Nat. Genet. 2012 44 760 764 10.1038/ng.2291 22634756 · DOI
  77. [80]Monga S.P. beta-Catenin Signaling and Roles in Liver Homeostasis, Injury, and Tumorigenesis Gastroenterology 2015 148 1294 1310 10.1053/j.gastro.2015.02.056 25747274 PMC4494085 · DOI
  78. [81]Bruix J. Han K.H. Gores G. Llovet J.M. Mazzaferro V. Liver cancer: Approaching a personalized care J. Hepatol. 2015 62 S144 S156 10.1016/j.jhep.2015.02.007 25920083 PMC4520430 · DOI
  79. [82]Perugorria M.J. Olaizola P. Labiano I. Esparza-Baquer A. Marzioni M. Marin J.J.G. Bujanda L. Banales J.M. Wnt-beta-catenin signalling in liver development, health and disease Nat. Rev. Gastroenterol. Hepatol. 2019 16 121 136 10.1038/s41575-018-0075-9 30451972 · DOI
  80. [83]Kim E. Lisby A. Ma C. Lo N. Ehmer U. Hayer K.E. Furth E.E. Viatour P. Promotion of growth factor signaling as a critical function of beta-catenin during HCC progression Nat. Commun. 2019 10 1909 10.1038/s41467-019-09780-z 31015417 PMC6478918 · DOI
  81. [84]Fodde R. Smits R. Clevers H. APC, signal transduction and genetic instability in colorectal cancer Nat. Rev. Cancer 2001 1 55 67 10.1038/35094067 11900252 · DOI · Paper page
  82. [85]Pez F. Lopez A. Kim M. Wands J.R. Caron de Fromentel C. Merle P. Wnt signaling and hepatocarcinogenesis: Molecular targets for the development of innovative anticancer drugs J. Hepatol. 2013 59 1107 1117 10.1016/j.jhep.2013.07.001 23835194 · DOI
  83. [86]Zhi X. Lin L. Yang S. Bhuvaneshwar K. Wang H. Gusev Y. Lee M.H. Kallakury B. Shivapurkar N. Cahn K. betaII-Spectrin (SPTBN1) suppresses progression of hepatocellular carcinoma and Wnt signaling by regulation of Wnt inhibitor kallistatin Hepatology 2015 61 598 612 10.1002/hep.27558 25307947 PMC4327990 · DOI
  84. [87]Chai S. Ng K.Y. Tong M. Lau E.Y. Lee T.K. Chan K.W. Yuan Y.F. Cheung T.T. Cheung S.T. Wang X.Q. Octamer 4/microRNA-1246 signaling axis drives Wnt/beta-catenin activation in liver cancer stem cells Hepatology 2016 64 2062 2076 10.1002/hep.28821 27639189 · DOI
  85. [88]Jain S. Chang T.T. Hamilton J.P. Lin S.Y. Lin Y.J. Evans A.A. Selaru F.M. Lin P.W. Chen S.H. Block T.M. Methylation of the CpG sites only on the sense strand of the APC gene is specific for hepatocellular carcinoma PLoS ONE 2011 6 e26799 10.1371/journal.pone.0026799 22073196 PMC3206845 · DOI
  86. [89]Loilome W. Bungkanjana P. Techasen A. Namwat N. Yongvanit P. Puapairoj A. Khuntikeo N. Riggins G.J. Activated macrophages promote Wnt/beta-catenin signaling in cholangiocarcinoma cells Tumour Biol. 2014 35 5357 5367 10.1007/s13277-014-1698-2 24549785 PMC4862210 · DOI
  87. [90]Boulter L. Guest R.V. Kendall T.J. Wilson D.H. Wojtacha D. Robson A.J. Ridgway R.A. Samuel K. Van Rooijen N. Barry S.T. WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited J. Clin. Invest. 2015 125 1269 1285 10.1172/JCI76452 25689248 PMC4362247 · DOI
  88. [91]Goeppert B. Konermann C. Schmidt C.R. Bogatyrova O. Geiselhart L. Ernst C. Gu L. Becker N. Zucknick M. Mehrabi A. Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway Hepatology 2014 59 544 554 10.1002/hep.26721 24002901 · DOI
  89. [92]Zhang F. Wan M. Xu Y. Li Z. Leng K. Kang P. Cui Y. Jiang X. Long noncoding RNA PCAT1 regulates extrahepatic cholangiocarcinoma progression via the Wnt/beta-catenin-signaling pathway Biomed Pharm. 2017 94 55 62 10.1016/j.biopha.2017.07.025 28753454 · DOI
  90. [93]Huang G.L. Luo Q. Rui G. Zhang W. Zhang Q.Y. Chen Q.X. Shen D.Y. Oncogenic activity of retinoic acid receptor gamma is exhibited through activation of the Akt/NF-kappaB and Wnt/beta-catenin pathways in cholangiocarcinoma Mol. Cell. Biol. 2013 33 3416 3425 10.1128/MCB.00384-13 23798555 PMC3753848 · DOI
  91. [94]Merino-Azpitarte M. Lozano E. Perugorria M.J. Esparza-Baquer A. Erice O. Santos-Laso A. O’Rourke C.J. Andersen J.B. Jimenez-Aguero R. Lacasta A. SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma J. Hepatol. 2017 67 72 83 10.1016/j.jhep.2017.02.017 28237397 PMC5502751 · DOI
  92. [95]Wang J. Zhang K. Wang J. Wu X. Liu X. Li B. Zhu Y. Yu Y. Cheng Q. Hu Z. Underexpression of LKB1 tumor suppressor is associated with enhanced Wnt signaling and malignant characteristics of human intrahepatic cholangiocarcinoma Oncotarget 2015 6 18905 18920 10.18632/oncotarget.4305 26056085 PMC4662463 · DOI
  93. [96]Russell J.O. Monga S.P. Wnt/beta-Catenin Signaling in Liver Development, Homeostasis, and Pathobiology Annu. Rev. Pathol. 2018 13 351 378 10.1146/annurev-pathol-020117-044010 29125798 PMC5927358 · DOI · Paper page
  94. [97]Dubbink H.J. Hollink I. Avenca Valente C. Wang W. Liu P. Doukas M. van Noesel M.M. Dinjens W.N.M. Wagner A. Smits R. A novel tissue-based ss-catenin gene and immunohistochemical analysis to exclude familial adenomatous polyposis among children with hepatoblastoma tumors Pediatr. Blood Cancer 2018 65 e26991 10.1002/pbc.26991 29446530 · DOI
  95. [98]Adebayo Michael A.O. Ko S. Tao J. Moghe A. Yang H. Xu M. Russell J.O. Pradhan-Sundd T. Liu S. Singh S. Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by beta-Catenin Mutations Cell Metab. 2019 29 1135 1150 10.1016/j.cmet.2019.01.002 30713111 PMC6506359 · DOI · Paper page
  96. [99]Wei W. Chua M.S. Grepper S. So S.K. Soluble Frizzled-7 receptor inhibits Wnt signaling and sensitizes hepatocellular carcinoma cells towards doxorubicin Mol. Cancer 2011 10 16 10.1186/1476-4598-10-16 21314951 PMC3050858 · DOI
  97. [100]Jimeno A. Gordon M. Chugh R. Messersmith W. Mendelson D. Dupont J. Stagg R. Kapoun A.M. Xu L. Uttamsingh S. A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors Clin. Cancer Res. 2017 23 7490 7497 10.1158/1078-0432.CCR-17-2157 28954784 · DOI
  98. [105]Arafat K. Iratni R. Takahashi T. Parekh K. Al Dhaheri Y. Adrian T.E. Attoub S. Inhibitory Effects of Salinomycin on Cell Survival, Colony Growth, Migration, and Invasion of Human Non-Small Cell Lung Cancer A549 and LNM35: Involvement of NAG-1 PLoS ONE 2013 8 e66931 10.1371/journal.pone.0066931 23805285 PMC3689654 · DOI
  99. [106]Lu W. Li Y. Salinomycin suppresses LRP6 expression and inhibits both Wnt/beta-catenin and mTORC1 signaling in breast and prostate cancer cells J. Cell. Biochem. 2014 115 1799 1807 10.1002/jcb.24850 24905570 PMC4134741 · DOI
  100. [107]Mao J. Fan S. Ma W. Fan P. Wang B. Zhang J. Wang H. Tang B. Zhang Q. Yu X. Roles of Wnt/beta-catenin signaling in the gastric cancer stem cells proliferation and salinomycin treatment Cell Death Dis. 2014 5 e1039 10.1038/cddis.2013.515 24481453 PMC4040703 · DOI
  101. [108]Tang Q.L. Zhao Z.Q. Li J.C. Liang Y. Yin J.Q. Zou C.Y. Xie X.B. Zeng Y.X. Shen J.N. Kang T. Salinomycin inhibits osteosarcoma by targeting its tumor stem cells Cancer Lett. 2011 311 113 121 10.1016/j.canlet.2011.07.016 21835542 · DOI
  102. [109]Wang F. Dai W. Wang Y. Shen M. Chen K. Cheng P. Zhang Y. Wang C. Li J. Zheng Y. The synergistic in vitro and in vivo antitumor effect of combination therapy with salinomycin and 5-fluorouracil against hepatocellular carcinoma PLoS ONE 2014 9 e97414 10.1371/journal.pone.0097414 24816638 PMC4016361 · DOI
  103. [110]Wang F. He L. Dai W.Q. Xu Y.P. Wu D. Lin C.L. Wu S.M. Cheng P. Zhang Y. Shen M. Salinomycin inhibits proliferation and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo PLoS ONE 2012 7 e50638 10.1371/journal.pone.0050638 23284640 PMC3527475 · DOI
  104. [111]Wei W. Chua M.S. Grepper S. So S.K. Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells Mol. Cancer 2009 8 76 10.1186/1476-4598-8-76 19778454 PMC2759906 · DOI
  105. [112]He B. Reguart N. You L. Mazieres J. Xu Z. Lee A.Y. Mikami I. McCormick F. Jablons D.M. Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations Oncogene 2005 24 3054 3058 10.1038/sj.onc.1208511 15735684 · DOI
  106. [113]He B. You L. Uematsu K. Xu Z. Lee A.Y. Matsangou M. McCormick F. Jablons D.M. A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells Neoplasia 2004 6 7 14 10.1016/S1476-5586(04)80048-4 15068666 PMC1508626 · DOI
  107. [114]Mikami I. You L. He B. Xu Z. Batra S. Lee A.Y. Mazieres J. Reguart N. Uematsu K. Koizumi K. Efficacy of Wnt-1 monoclonal antibody in sarcoma cells BMC Cancer 2005 5 53 10.1186/1471-2407-5-53 15913453 PMC1164405 · DOI
  108. [115]Rhee C.S. Sen M. Lu D. Wu C. Leoni L. Rubin J. Corr M. Carson D.A. Wnt and frizzled receptors as potential targets for immunotherapy in head and neck squamous cell carcinomas Oncogene 2002 21 6598 6605 10.1038/sj.onc.1205920 12242657 · DOI
  109. [116]Hu J. Dong A. Fernandez-Ruiz V. Shan J. Kawa M. Martinez-Anso E. Prieto J. Qian C. Blockade of Wnt signaling inhibits angiogenesis and tumor growth in hepatocellular carcinoma Cancer Res. 2009 69 6951 6959 10.1158/0008-5472.CAN-09-0541 19690140 · DOI
  110. [122]Bendell J.C. Murphy J.E. Mahalingam D. Halmos B. Sirard C.A. Landau S.B. Ryan D.P. A Phase 1 study of DKN-01, an anti-DKK1 antibody, in combination with paclitaxel (pac) in patients with DKK1 relapsed or refractory esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ) J. Clin. Oncol. 2016 34 111 10.1200/jco.2016.34.4_suppl.111 · DOI
  111. [127]Li C. Cao J. Zhang N. Tu M. Xu F. Wei S. Chen X. Xu Y. Identification of RSPO2 Fusion Mutations and Target Therapy Using a Porcupine Inhibitor Sci. Rep. 2018 8 14244 10.1038/s41598-018-32652-3 30250044 PMC6155119 · DOI
  112. [128]Wang W. Xu L. Liu P. Jairam K. Yin Y. Chen K. Sprengers D. Peppelenbosch M.P. Pan Q. Smits R. Blocking Wnt Secretion Reduces Growth of Hepatocellular Carcinoma Cell Lines Mostly Independent of beta-Catenin Signaling Neoplasia 2016 18 711 723 10.1016/j.neo.2016.10.004 27851986 PMC5110474 · DOI
  113. [129]Ma L. Wang X. Jia T. Wei W. Chua M.S. So S. Tankyrase inhibitors attenuate WNT/beta-catenin signaling and inhibit growth of hepatocellular carcinoma cells Oncotarget 2015 6 25390 25401 10.18632/oncotarget.4455 26246473 PMC4694839 · DOI
  114. [130]Gwak J. Lee J.H. Chung Y.H. Song G.Y. Oh S. Small molecule-based promotion of PKCalpha-mediated beta-catenin degradation suppresses the proliferation of CRT-positive cancer cells PLoS ONE 2012 7 e46697 10.1371/journal.pone.0046697 23071615 PMC3465275 · DOI
  115. [131]Zeng G. Apte U. Cieply B. Singh S. Monga S.P. siRNA-mediated beta-catenin knockdown in human hepatoma cells results in decreased growth and survival Neoplasia 2007 9 951 959 10.1593/neo.07469 18030363 PMC2077886 · DOI
  116. [132]Li Y. Rogoff H.A. Keates S. Gao Y. Murikipudi S. Mikule K. Leggett D. Li W. Pardee A.B. Li C.J. Suppression of cancer relapse and metastasis by inhibiting cancer stemness Proc. Natl. Acad. Sci. USA 2015 112 1839 1844 10.1073/pnas.1424171112 25605917 PMC4330785 · DOI
  117. [137]Kimura K. Ikoma A. Shibakawa M. Shimoda S. Harada K. Saio M. Imamura J. Osawa Y. Kimura M. Nishikawa K. Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/beta-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial EBioMed. 2017 23 79 87 10.1016/j.ebiom.2017.08.016 PMC5605374 28844410 · DOI
  118. [138]Emami K.H. Nguyen C. Ma H. Kim D.H. Jeong K.W. Eguchi M. Moon R.T. Teo J.L. Kim H.Y. Moon S.H. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected] Proc. Natl. Acad. Sci. USA 2004 101 12682 12687 10.1073/pnas.0404875101 15314234 PMC515116 · DOI
  119. [139]Handeli S. Simon J.A. A small-molecule inhibitor of Tcf/beta-catenin signaling down-regulates PPARgamma and PPARdelta activities Mol. Cancer 2008 7 521 529 10.1158/1535-7163.MCT-07-2063 18347139 · DOI · Paper page
  120. [140]Wei W. Chua M.S. Grepper S. So S. Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo Int. J. Cancer 2010 126 2426 2436 10.1002/ijc.24810 19662654 · DOI
  121. [141]Lepourcelet M. Chen Y.N. France D.S. Wang H. Crews P. Petersen F. Bruseo C. Wood A.W. Shivdasani R.A. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex Cancer Cell 2004 5 91 102 10.1016/S1535-6108(03)00334-9 14749129 · DOI
  122. [142]Mologni L. Brussolo S. Ceccon M. Gambacorti-Passerini C. Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells PLoS ONE 2012 7 e51449 10.1371/journal.pone.0051449 23227266 PMC3515485 · DOI
  123. [143]Thompson M.D. Dar M.J. Monga S.P. Pegylated interferon alpha targets Wnt signaling by inducing nuclear export of beta-catenin J. Hepatol. 2011 54 506 512 10.1016/j.jhep.2010.07.020 21093092 PMC3052972 · DOI
  124. [144]Dhanasekaran R. Nault J.C. Roberts L.R. Zucman-Rossi J. Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy Gastroenterology 2019 156 492 509 10.1053/j.gastro.2018.11.001 30404026 PMC6340723 · DOI
  125. [145]Calderaro J. Couchy G. Imbeaud S. Amaddeo G. Letouze E. Blanc J.F. Laurent C. Hajji Y. Azoulay D. Bioulac-Sage P. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification J. Hepatol. 2017 67 727 738 10.1016/j.jhep.2017.05.014 28532995 · DOI
  126. [146]Boyault S. Rickman D.S. de Reynies A. Balabaud C. Rebouissou S. Jeannot E. Herault A. Saric J. Belghiti J. Franco D. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets Hepatology 2007 45 42 52 10.1002/hep.21467 17187432 · DOI · Paper page

Authors
Wang, W., Smits, R., Hao, H., & He, C.
Affiliations
  • China Pharmaceutical University (CN)
  • Erasmus MC (NL)
Corresponding author
  • Hao, Haiping
  • He, Chaoyong
ORCID
Venue
Cancers
Publisher
MDPI AG
Published
2019-07-02
Volume
11
Issue
7
Pages
926
ISSN
2072-6694 (ISSN-L)
DOI
10.3390/cancers11070926
PMC
PMC6679127
OpenAlex
W2954673706
Cited by
143
References
130
Citations by year
2026: 5 · 2025: 8 · 2024: 16 · 2023: 25 · 2022: 33 · 2021: 35 · 2020: 18 · 2019: 3
FWCI
1.96
Type
journal article
Language
en
Open access
Licence
Locations
  • Cancers (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (acceptedVersion, cc-by)
  • RePub (Erasmus University Rotterdam) (submittedVersion, cc-by)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (81670425)
  • ‘‘Double First Class’’ University Project of China Pharmaceutical University (CPU2018GF04)
  • Open Project of State Key Laboratory of Natural Medicines of China Pharmaceutical University (3144060173)
  • Fundamental Research Funds for the Central Universities (3011900173)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
Wnt/β-catenin signaling, liver cancer, hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, liver cancer pathogenesis, precancerous lesions, small molecule inhibitors, biologic agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review